
    
      A randomized, positive-control, multicenter, multiple-dose, dose-escalation phase II trial.
      The trial was divided into 4 dose groups: the positive drug Kaishi 10 μg group and the
      alprostadil liposome for injection 40μg, 80μg, 120μg group.
    
  